Literature DB >> 22903440

Effect of Shengmai injection () on diaphragmatic contractility in doxorubicin-treated rats.

Min Ge1, Ying-yan Fang, Guo-ping Liu, Su-dong Guan.   

Abstract

OBJECTIVE: To explore the diaphragmatic toxicity in doxorubicin (DOX)-treated rats and the related mechanisms, as well as the effects of Shengmai Injection (SMI, ) on the diaphragmatic dysfunction.
METHODS: Thirty Sprague-Dawley male rats were randomly divided into three groups: control, DOX-treated and DOX+SMI treated groups. DOX was given to rats in DOX and DOX+SMI groups in 6 equal doses [2.5 mg/kg, intraperitoneal injection (i.p.)], on alternate days, over a period of 2 weeks for a cumulative dose of 15 mg/kg. SMI was given to DOX+SMI rats in 12 doses (3 mL/kg, i.p.) for a period of 2 weeks before the administration of DOX and 2 weeks during the administration of DOX. The rats in the control group received equal volume of normal saline. Subsequently, the twitch and tetanic characteristics and force-frequency relationships, and the malondialdehyde (MDA) levels and the superoxide dismutase (SOD) activities, as well as the mRNA content and proteins of inducible nitric oxide synthase (iNOS) were determined.
RESULTS: The DOX-treated rats had decreased the peak twitch tension (Pt), maximal tetanic tension (P0) and force-frequency relationship as compared with the control rats (P<0.01), while the diaphragm contractility in rats treated with SMI were significantly higher than that in DOX-treated rats (P<0.01). The DOX-treated rats had increased MAD levels and decreased SOD activities (P<0.05), and SMI decreased the MDA levels and increased the SOD activities in DOX-treated rats (P<0.05). Ultrastructure of diaphragm in the DOX-treated rats revealed typical alterations including fracture of diaphragm fibers, and edema and degeneration of mitochondria; these changes were relieved by SMI treatment. The mRNA content and protein of iNOS in DOX-treated rats were remarkably higher than those in control rats (P<0.01), while SMI decreased the mRNA expression level of iNOS in DOX-treated rats (P<0.05).
CONCLUSIONS: Lipid peroxidation is responsible for DOX-induced diaphragm toxicity. SMI protects diaphragm muscles and their function from DOX impairment, and these beneficial effects may be somehow correlated with the decrease in expression of iNOS and lipid peroxidation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22903440     DOI: 10.1007/s11655-012-1096-9

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  14 in total

Review 1.  Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review.

Authors:  E L De Beer; A E Bottone; E E Voest
Journal:  Eur J Pharmacol       Date:  2001-03-09       Impact factor: 4.432

2.  Nitric oxide effects on shortening velocity and power production in the rat diaphragm.

Authors:  R J Morrison; C C Miller; M B Reid
Journal:  J Appl Physiol (1985)       Date:  1996-03

3.  Augmented expression of neuronal nitric oxide synthase in the atria parasympathetically decreases heart rate during acute myocardial infarction in rats.

Authors:  Yoshihito Takimoto; Takeshi Aoyama; Koichi Tanaka; Reiko Keyamura; Yoshiki Yui; Shigetake Sasayama
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

Review 4.  Vitamin E in the prevention of ischemic heart disease.

Authors:  Aindrila Chattopadhyay; Debashis Bandyopadhyay
Journal:  Pharmacol Rep       Date:  2006 Mar-Apr       Impact factor: 3.024

5.  Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats.

Authors:  Baogang Liu; Hongli Li; Hongyan Qu; Baogui Sun
Journal:  J Biochem Mol Biol       Date:  2006-11-30

6.  Free radicals in hypoxic rat diaphragm contractility: no role for xanthine oxidase.

Authors:  L M Heunks; H A Machiels; R de Abreu; X P Zhu; H F van der Heijden; P N Dekhuijzen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-12       Impact factor: 5.464

Review 7.  Doxorubicin-induced apoptosis: implications in cardiotoxicity.

Authors:  B Kalyanaraman; Joy Joseph; Shashi Kalivendi; Suwei Wang; Eugene Konorev; Srigiridhar Kotamraju
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

8.  Ultrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity.

Authors:  J H Doroshow; C Tallent; J E Schechter
Journal:  Am J Pathol       Date:  1985-02       Impact factor: 4.307

9.  Shengmai San reduces hepatic lipids and lipid peroxidation in rats fed on a high-cholesterol diet.

Authors:  Hsien-Tsung Yao; Yi-Wei Chang; Chiung-Tong Chen; Meng-Tsan Chiang; Ling Chang; Teng-Kuang Yeh
Journal:  J Ethnopharmacol       Date:  2007-11-13       Impact factor: 4.360

10.  Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies.

Authors:  Semon Wu; Yu-Shien Ko; Ming-Sheng Teng; Yu-Lin Ko; Lung-An Hsu; Chuen Hsueh; Yung-Yin Chou; Choong-Chin Liew; Ying-Shiung Lee
Journal:  J Mol Cell Cardiol       Date:  2002-12       Impact factor: 5.000

View more
  4 in total

1.  The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle.

Authors:  Laura A A Gilliam; Kelsey H Fisher-Wellman; Chien-Te Lin; Jill M Maples; Brook L Cathey; P Darrell Neufer
Journal:  Free Radic Biol Med       Date:  2013-09-07       Impact factor: 7.376

2.  A metabolomic study of rats with doxorubicin-induced cardiomyopathy and Shengmai injection treatment.

Authors:  Yu Chen; Yong Tang; Ya-Chen Zhang; Xiao-Hong Huang; Yu-Quan Xie; Yin Xiang
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

Review 3.  Doxorubicin-induced skeletal muscle atrophy: Elucidating the underlying molecular pathways.

Authors:  Anouk E Hiensch; Kate A Bolam; Sara Mijwel; Jeroen A L Jeneson; Alwin D R Huitema; Onno Kranenburg; Elsken van der Wall; Helene Rundqvist; Yvönne Wengstrom; Anne M May
Journal:  Acta Physiol (Oxf)       Date:  2019-10-31       Impact factor: 6.311

Review 4.  Ginseng and anticancer drug combination to improve cancer chemotherapy: a critical review.

Authors:  Shihong Chen; Zhijun Wang; Ying Huang; Stephen A O'Barr; Rebecca A Wong; Steven Yeung; Moses Sing Sum Chow
Journal:  Evid Based Complement Alternat Med       Date:  2014-04-30       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.